Literature DB >> 20736047

Nitric oxide synthase (NOS) in the trigeminal vascular system and other brain structures related to pain in rats.

Roshni Ramachandran1, Kenneth Beri Ploug, Anders Hay-Schmidt, Jes Olesen, Inger Jansen-Olesen, Saurabh Gupta.   

Abstract

Nitric oxide (NO) is considered to be a key mediator in the pathophysiology of migraine but the localisation of NO synthesizing enzymes (NOS) throughout the pain pathways involved in migraine has not yet been fully investigated. We have used quantitative real-time PCR and Western blotting to measure the respective levels of mRNA and protein for nNOS and eNOS in peripheral and central tissues involved in migraine pain: dura mater, pial arteries, trigeminal ganglion (TG) trigeminal nucleus caudalis (TNC), periaqueductal grey (PAG), thalamus, hypothalamus, cortex, pituitary gland, hippocampus and cerebellum. iNOS was excluded from the present study because it was not induced. In the trigeminal vascular system we found the highest expression of nNOS mRNA in pial arteries. However, protein expression of nNOS was maximum in TNC. Among other brain structures, nNOS mRNA and protein expression was remarkably higher in the cerebellum than in any other tissues. Regarding eNOS in the trigeminovascular system, the highest mRNA expression was found in pial arteries. In the other brain structures, eNOS mRNA expression was similar but with lowest mRNA concentration in the pituitary gland and the highest concentration in cortex. The same pattern of expression was also observed with the eNOS protein. In conclusion, we found both nNOS and eNOS located to areas relevant to migraine supporting the involvement of NO in migraine mechanisms. 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20736047     DOI: 10.1016/j.neulet.2010.08.050

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  18 in total

1.  Mechanism of Inactivation of Neuronal Nitric Oxide Synthase by (S)-2-Amino-5-(2-(methylthio)acetimidamido)pentanoic Acid.

Authors:  Wei Tang; Huiying Li; Emma H Doud; Yunqiu Chen; Stephanie Choing; Carla Plaza; Neil L Kelleher; Thomas L Poulos; Richard B Silverman
Journal:  J Am Chem Soc       Date:  2015-05-05       Impact factor: 15.419

Review 2.  Emerging Treatment Targets for Migraine and Other Headaches.

Authors:  Zachariah Bertels; Amynah Amir Ali Pradhan
Journal:  Headache       Date:  2019-07       Impact factor: 5.887

Review 3.  Targeted Nitric Oxide Synthase Inhibitors for Migraine.

Authors:  Amynah A Pradhan; Zachariah Bertels; Simon Akerman
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

4.  Genetic variations in interleukin-8 and interleukin-10 are associated with pain, depressed mood, and fatigue in lung cancer patients.

Authors:  Cielito C Reyes-Gibby; Jian Wang; Margaret Spitz; Xifeng Wu; Sriram Yennurajalingam; Sanjay Shete
Journal:  J Pain Symptom Manage       Date:  2012-11-11       Impact factor: 3.612

5.  Optimization of combinations of ginsenoside-Rg1, ginsenoside-Rb1, evodiamine and rutaecarpine for effective therapy of mouse migraine.

Authors:  Yanchuan Wu; Xueqiang Pan; Yongsong Xu; Xuran Lu; Shida He; Rui He; Muxin Gong
Journal:  J Nat Med       Date:  2015-12-28       Impact factor: 2.343

6.  Effects of inducible nitric oxide synthase blockade within the periaqueductal gray on cardiovascular responses during mechanical, heat, and cold nociception.

Authors:  Kevin A Chaitoff; Francis Toner; Anthony Tedesco; Timothy J Maher; Ahmmed Ally
Journal:  Neurol Sci       Date:  2011-06-28       Impact factor: 3.307

Review 7.  Neurogenic inflammation and its role in migraine.

Authors:  Roshni Ramachandran
Journal:  Semin Immunopathol       Date:  2018-03-22       Impact factor: 9.623

8.  Triiodothyronine differentially modulates the LH and FSH synthesis and secretion in male rats.

Authors:  Renata Marino Romano; Paula Bargi-Souza; Erika Lia Brunetto; Francemilson Goulart-Silva; Renato M Salgado; Telma Maria Tenorio Zorn; Maria Tereza Nunes
Journal:  Endocrine       Date:  2017-12-05       Impact factor: 3.633

Review 9.  Development of nitric oxide synthase inhibitors for neurodegeneration and neuropathic pain.

Authors:  Paramita Mukherjee; Maris A Cinelli; Soosung Kang; Richard B Silverman
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

10.  Epistasis between polymorphisms in COMT, ESR1, and GCH1 influences COMT enzyme activity and pain.

Authors:  Shad B Smith; Ilkka Reenilä; Pekka T Männistö; Gary D Slade; William Maixner; Luda Diatchenko; Andrea G Nackley
Journal:  Pain       Date:  2014-09-16       Impact factor: 6.961

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.